对于非创伤性骨髓灰质炎的药理管理,潜在的分子标
Edward Y Cheng1, Alireza Mirzaei1
1Department of Orthopedic Surgery, University of Minnesota, Minneapolis, MN, USA.
Expert opinion on therapeutic targets
|October 29, 2024
概括
非创伤性骨 necrosis,一个骨死亡的条件,缺乏有效的药物治疗. 研究表明,针对多种疾病的原因是开发新疗法的关键.
科学领域:
- 生物医学研究的研究.
- 药理学 药理学是指药理学的学科.
- 整形外科 整形外科 整形外科
背景情况:
- 非创伤性骨髓缩包括由于血液供应不足而导致的骨死亡.
- 目前针对非创伤性骨髓缩的药理干预措施是无效的.
- 了解致病机制对于开发新疗法至关重要.
研究的目的:
- 为了编制非创伤性骨髓缩的病原性机制.
- 确定药理干预的潜在治疗点.
- 审查治疗非创伤性骨髓缩的分子标.
主要方法:
- 对致病机制的数据库审查.
- 确定相应的治疗目标.
- 对非创伤性骨硬化分子标的分析.
主要成果:
- 关键的致病机制包括脂质乱,炎症,血管功能障碍,凝血病和骨质平衡受损.
- 多种致病机制有助于骨质死结的发展.
- 没有一个单一的机制可以解释所有病例;需要针对病因学的具体方法.
结论:
- 有效的非创伤性骨 necrosis 管理需要同时针对多种致病机制.
- 一种适合所有人的药理学方法不太可能有效.
- 未来的研究应该专注于针对特定骨髓灰质炎病因量身定制的多目标治疗方法.
相关概念视频
Targets for Drug Action: Overview
6.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.1K
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
Osteoclasts in Bone Remodeling
2.8K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
2.8K
Analgesia and Pain Management
534
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
534
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K


